MIRM Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -10.38%, SMA50 0.84%, SMA200 32.39%). The stock’s 14-day RSI is 38.75 (weak momentum), while the ATR of 4.57 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -15.64% below its high and over 149.97% above its low. Average 10-day trading volume of 903.97 thousand shares is slightly above the 3-month average of 802.66 thousand, indicating heightened recent market interest.

Mirum Pharmaceuticals, Inc. has 50.24 million shares outstanding. The public float is 39.99 million shares, elevated short interest at 13.25% of float. This equals 6.63 million shares. The short ratio is 17.23 days. Institutional investors hold 106.15% of the float. Insiders own 1.33%. BARRIS PETER J holds 4.19 million shares, Behbahani Ali has 4.19 million shares and Walker Paul Edward has 4.19 million shares. Over the past six months, insider transactions show net selling. They sold 285.94 thousand shares across 27 transactions.

Mirum Pharmaceuticals, Inc. generated EPS of -$0.86 over the past year. Five-year average earnings growth is 4.14%. The latest quarter delivered EPS of -$0.11. The next quarter is forecast at -$0.21. Next year's EPS is expected at $93.32. Analyst sentiment is bullish. Analyst rating data shows there are 19 Strong Buy ratings, 14 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $175.00 to $77.00. The high target offers 65.42% upside. The low target suggests -27.21% downside. The mean target is $110.82. This offers 4.75% upside. Mirum Pharmaceuticals, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended February 25, 2026, missed forecasts by -650.0%. The prior quarter beat by -150.0%. Over the last six quarters, Apple has recorded several small beats. These include -33.33% in November 12, 2024.

Mirum Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.79. This means the shares are trading above this model’s fair value.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) closed at $105.79 USD, gaining $9.26 (9.59%) from the previous close of $96.53. The stock is currently within 5% of its 52-week high $40.00 and $110.48. With a market capitalization of about $5.31 billion, Mirum Pharmaceuticals, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.52). Key stats such as the average daily volume over the past year has been around 793.66 thousand shares, trading with heavier-than-usual volume. Headquartered in Foster City, CA, Mirum Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Christopher Peetz, the company employs approximately 334 people and listed since July 18, 2019. Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.

Mirum Pharmaceuticals, Inc. trades at a P/E ratio of -230.48, slightly below the S&P 500 average, with a price-to-sales ratio of 10.33 and a price-to-book ratio of 17.11 reflecting a rich premium to book value. The P/FCF stands at 98.13, also below market averages. Compared to sector medians, Mirum Pharmaceuticals, Inc. P/S is trading rich, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) shares are up 16.33% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Mirum Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -230.48. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $76.89, suggesting -27.32% downside. Our AI forecast model points to short-term weakness (-11.34% over two weeks), a medium-term rise (18.49% over three months), and a longer-term gain (13.61% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Mirum Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -11.34%, with price expected at $93.79 by May 14, 2026, within a range of $91.07 to $96.50 3-Month Outlook: Projected rise of 18.49%, reaching $125.35 by July 29, 2026, with a range of $124.07 to $126.49. 1-Year Outlook: Projected gain of 13.61%, with price at $120.19 by April 30, 2027, within a range of $116.54 to $124.17.